Drug Profile
Research programme: Trident tri-specific antibodies - MacroGenics
Alternative Names: 5T4 x CD137 x CD137Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator MacroGenics
- Class Proteins; Trispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 29 Mar 2019 Pharmacodynamics data from a preclinical study in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
- 29 Nov 2018 An undisclosed TRIDENT™ molecule licensed to Zai Lab in China, Hong Kong, Macau and Taiwan